^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy

Published date:
11/04/2020
Excerpt:
We identified 290 consecutive adult patients treated with standard induction chemotherapy (“7+3” with cytarabine and an anthracycline, or CPX-351) for newly diagnosed AML...the presence of TP53 mutation, U2AF1 mutation, or 11q23 rearrangement were independently associated with inferior OS after day 60, whereas the presence of CBF rearrangement was independently associated with superior OS after day 60...
DOI:
10.1182/blood-2020-138817